Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 57 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
PHARMACIE MONTENEGRO from Anderlecht, company number BE0764411765, closed financial year 2025 with a result of € 15,996 after tax. For that financial year PHARMACIE MONTENEGRO recorded a gross margin of € 248,171 and equity of € 81,129. Compared with financial year 2024, the result moved from € -6,054 to € 15,996. Profitable, and profit is growing. The buffer is growing. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 81,129
▲ 25% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 15,996
▲ still € 6,054 loss in 2024
Profit after tax over the fiscal year.
€ 84,925
▲ 37% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € -18,871.
People and assets in 2025
2.5
▼ 0.1 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 116,352
▲ 7% vs 2024
€ 46,500 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 13,419
▼ 8% vs 2024
Of which on lease € 5,781.
Debts at end 2025
€ 348,964
▼ 16% vs 2024
€ 63,576 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 98,533
▼ 13% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 84,969
▲ 96% vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 235,799 | € 152,106 | € 203,592 | € 248,171 | ▲ 22% |
| Profit after taxes | € 8,691 | € -44,224 | € -6,054 | € 15,996 | ▲ € 22,050 |
| Equity | € 115,412 | € 71,188 | € 65,134 | € 81,129 | ▲ 25% |
| Total debts | € 1,045,671 | € 877,633 | € 774,436 | € 709,997 | ▼ 8% |
| Cash | € 296,373 | € 136,042 | € 62,201 | € 84,925 | ▲ 37% |
| Retained profit | € 15,412 | € -28,812 | € -34,866 | € -18,871 | ▲ € 15,996 |
| Bank debt | € 539,529 | € 477,038 | € 413,545 | € 348,964 | ▼ 16% |
| Balance sheet total | € 1,161,083 | € 948,820 | € 839,570 | € 791,126 | ▼ 6% |
| Employees (FTE) | 1.9 | 1.9 | 2.6 | 2.5 | ▼ 0.1 |
Key figures of PHARMACIE MONTENEGRO, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to PHARMACIE MONTENEGRO?
What happened at PHARMACIE MONTENEGRO in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 15,996. filed late Source: NBB ↗
- New establishment in Vorst. KBO
- Start of the company according to the CBE. KBO
In short
From € 8,691 profit in 2022 to € 15,996 profit in 2025.
Paid € 76,151 in corporate taxes since 2022.
Best year ever: 2025, with € 15,996 profit.
On average € 99,300 of value added per employee in 2025.
A new publication or filing at PHARMACIE MONTENEGRO? We notify you, reason included.
Follow PHARMACIE MONTENEGRODatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind PHARMACIE MONTENEGRO are ALI EMDADI MILAD and ZACHARIA BOUMEDIENNI. The same people are also behind PHARMATRUST, PHARMA DISCOUNT and Pharmacie Armée Britannique. ALI EMDADI MILAD is also behind PHARMALAW.
Directors
According to the 2025 annual accounts
ALI EMDADI MILAD
Director
Also active at: PHARMALAW, PHARMATRUST, PHARMA DISCOUNT, Pharmacie Armée Britannique
ZACHARIA BOUMEDIENNI
Director
Also active at: PHARMATRUST, PHARMA DISCOUNT, Pharmacie Armée Britannique
Establishments
Establishment units
Physical locations of this company
Agavendreef 9
1070 Anderlecht
de Mérodestraat 378
1190 Vorst
Active since 26 February 2021
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 4 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0764.411.765
- VAT number
- BE 0764.411.765
- Registered office
- Agavendreef 9, 1070 Anderlecht
- Names & denominations
- PHARMACIE MONTENEGRO
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 26 February 2021
- Peppol
- Active · Active since 12 Sept 2025
- Contact
- [email protected] +32484431889
- Activities · NACE
Detailhandel in farmaceutische producten
Activiteiten van holdings
Holdings